This study was conducted to investigate the association of maternal and/or fetal factor V Leiden (FVL) and G20210A prothrombin mutation with HELLP syndrome. FVL and G20210A prothrombin mutation were determined using PCR. Sixty-three pregnant women, 36 of them diagnosed with HELLP syndrome, were included in the study. Overall, 68 children were born as a result of these pregnancies and blood sampling was possible in 28 out of 39 children from HELLP patients and 25 out of 29 children from the control women. The prevalence of a maternal FVL was elevated 2-fold in HELLP patients compared with the control women [six out of 36 (16.7 %) compared with two out of 27 (7.4 %); P = 0.282]. None of the HELLP patients and only one woman in the control group was found to be positive for the G20210A prothrombin mutation (P = 0.251). The fetal carrier frequency was four out of 28 compared with three out of 25 for FVL (P = 0.811), and two out of 28 compared with one out of 25 for G20210A prothrombin mutation (P = 0.629). Intrauterine growth restriction (IUGR) was significantly higher in fetuses found to be positive for a thrombophilic mutation (P = 0.022). IUGR occurred in seven out of ten fetuses with a thrombophilic mutation compared with 11 out of 43 in fetuses without a mutation. The prevalence of FVL, but not of the G20210A prothrombin mutation, seems to be elevated in women with HELLP syndrome. A fetal thrombophilic mutation does not contribute significantly to the clinical features of the HELLP syndrome. Our results demonstrate a fetal contribution to IUGR. Fetal thrombophilic mutations may lead to placental microthrombosis, which consecutively could lead to a disturbed fetoplacental blood flow and thus cause growth restriction.
INTRODUCTION
The aetiology and pathogenesis of HELLP syndrome (haemolysis, elevated liver enzymes and low platelet subsequently, to an inadequate maternal-fetal circulation [1] .
Several genetic mutations have been identified in patients with inherited thrombophilia. The factor V Leiden (FVL) mutation is the most common genetic cause of resistance to activated protein C and has been linked with an increased risk of venous thromboembolism especially in pregnancy [2] . It arises from a point mutation in the factor V gene at its site of cleavage (inactivation) by protein C. An A 1691 → G mutation in the tenth exon in the factor V gene results in an Arg 506 → Gln replacement in the factor V polypeptide. The resultant amino acid substitution impairs the ability to inactivate factor Va [3, 4] . A G 20210 → A (G20210A) mutation in the 3 -untranslated region of the prothrombin gene is also associated with an increased risk of venous thromboembolism [2] . In that case, factor Xa/Va complex cannot convert prothrombin into thrombin [5] .
Although several studies have demonstrated that serious obstetrical complications, such as thromboembolic disease, pre-eclampsia, abruptio placentae, IUGR or stillbirth, were frequently associated with these mutations [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , only one study [17] has investigated exclusively the prevalence of FVL in women with HELLP syndrome. Most recently, Benedetto et al. [16] reported a higher FVL prevalence in a subgroup of women with HELLP syndrome compared with pre-eclamptic women ( Table 1) .
The haemodynamic balance between maternal and fetal circulation is an important component of normal fetal development and pregnancy. A thrombophilic mutation of the fetus may disturb that balance and, therefore, contribute to the pathogenesis of these disorders. When conducting the present study, no information about the prevalence of these mutations in children born to mothers suffering from HELLP syndrome was available.
We hypothesized that these maternal and/or fetal thrombophilic mutations may be important risk factors for the pathogenesis of the HELLP syndrome leading to an inadequate maternal-fetal circulation. Consequently, we studied the prevalence of FVL and the G20210A prothrombin mutation in women with HELLP syndrome and their children born within this complicated pregnancy compared with pregnant women without HELLP syndrome.
MATERIALS AND METHODS

Study patients
A total of 65 women with HELLP syndrome were diagnosed and treated in the Department of Obstetrics and Gynaecology at the University Clinics of ErlangenNuremberg between 1995 and 2000. Of these women, 36 agreed to participate in the study and gave their informed written consent. The study was approved by the Local Ethics Committee. In 28 of the 39 children born to these mothers, the parents agreed to blood sampling, and blood sampling was possible without forcing the children. These children were tested for thrombophilic mutations. Women without HELLP syndrome (n = 27), who delivered in our Department, served as controls. Of these women, six of them were diagnosed to have preeclampsia, but no other criteria for HELLP syndrome occurred. In this control group, 25 (out of 29) children were examined. All women included in the study were of white Caucasian origin.
Definition criteria of HELLP syndrome, according to the Working Group on High Blood Pressure in Pregnancy [18] , were as follows: simultaneous occurrence of all symptoms after 20 weeks of gestation, i.e. platelet count less than 100 000 cells/µl, evidence of microangiopathic haemolytic anaemia (with increased lactate dehydrogenase > 200 units/l), elevated hepatic enzymes (alanine aminotransferase and aspartate aminotransferase > 20 units/l) and persistent epigastric pain.
In our Department, we perform a conservative management of HELLP syndrome by treatment with corticosteroids [19] . In those cases, we initiate therapy in women with obvious clinical HELLP syndrome prior to a platelet count of < 100 000/µl. In these cases, we used an alternative criterion (platelet count < 150 000/µl and rapid decrease in subsequent measurements).
In all study patients, IUGR was defined as fetal birth weight below the tenth percentile with respect to the standard growth curve for German speaking countries [20] .
Methods
DNA isolation and purification was performed using a modified salt precipitation method (Puregene DNA Isolation Kit; Gentra Systems Inc., Minneapolis, MN, U.S.A.). DNA was typed by a PCR-SSO Reverse Dot Blot Hybridization following group-specific amplification using a commercially available kit (Genome Identification Diagnostics GmbH, Strassberg, Germany). Briefly, 300 µl of whole blood or buffy coat was added to 900 µl of red blood cell lysis solution (Gentra Systems Inc.), mixed and incubated for 10 min at room temperature. The supernatant was removed after centrifugation at 13 400 g for 20 s to give a white blood cell pellet and 10-20 µl of residual liquid. White blood cells in the residual supernatant were vigorously mixed to resuspend them and 300 µl of cell lysis solution was added. Following cell lysis, 100 µl of protein precipitation solution (Gentra Systems Inc.) was added to the cell lysate, mixed at high speed for 20 s and centrifuged at 13 400 g for 3 min at room temperature. The precipitated proteins form a tight, dark brown pellet. For DNA precipitation, the supernatant containing the DNA was poured into a tube containing 300 µl of 100 % isopropanol (leaving behind the protein pellet), mixed gently and centrifuged for 1 min at 13 400 g at room temperature. The DNA is visible as a small white pellet. After pouring off the supernatant and draining the tube on clean paper, 300 µl of 70 % ethanol was added and centrifuged again for 1 min at 13 400 g at room temperature. The ethanol was carefully poured off and the tube inverted and drained on clean absorbent paper. The sample was allowed to air dry for 15 min. DNA hydration at room temperature was performed overnight by adding 100 µl of DNA hydration solution (Gentra Systems Inc.).
Co-amplification of the exon 10 region of factor-V and of the 3 -region of prothrombin (factor II) was performed on a DNA Thermal Cycler (Mastercycler ® gradient; Eppendorf-Netherler-Hinz GmbH, Hamburg, Germany). Amplified biotinylated DNA was then hybridized with sequence-specific oligonucleotide probes immobilized as parallel lines on nitrocellulose strips. After hybridization, streptavidin-labelled with alkaline phosphatase was added and bound to the biotinylated hybrides formed. After incubation with 5-bromo-4-chloroindol-3-yl phosphate/Nitro Blue Tetrazolium ('BCIP/NBT'), the complexes became visible and the 
Statistics
Statistical analysis was performed using the software package SPSS. Student's t test was applied to test differences between the two groups. Fisher Exact test was applied to test the association of thrombophilic mutations with IUGR. Differences were considered significant with P < 0.05. 
RESULTS
The characteristics of the study patients are shown in Table 2 . Gestational age at delivery and fetal birth weight were significantly lower in the HELLP group. Blood pressure was significantly elevated in the patients with HELLP as compared with controls. None of the women included in the study has been diagnosed to have severe comorbid diseases, such as diabetes, chronic hypertension, congenital heart disease, kidney diseases, asthma, connective tissue diseases or autoimmune diseases. Multifetal pregnancies occurred twice in both groups. No evidence of twin-twin transfusion syndrome occurred in either.
The prevalence and details of FVL and G20210A prothrombin mutation in the study groups are summarized in Table 3 . Overall, six women with HELLP syndrome and two women in the control group were found to be heterozygous carriers of FVL. The prevalence of a maternal FVL mutation was 16.7 % in women with HELLP syndrome and, therefore, elevated 2-fold compared with the control group (7.4 %; P = 0.282). However, a pregnancy complication did not occur in either of the two controls with the FVL mutation. The fetal carrier frequency of the FVL mutation was four out of 28 (14.3 %) in the HELLP syndrome group and three out of 25 (12.0 %) in the control group (P = 0.811). Three mothers and their children in the HELLP syndrome group and one mother and her child in the control group were identified both as being FVL carriers.
None of the 36 women with HELLP syndrome and only one of the 27 women in the control group was found to be a heterozygous carrier of the G20210A prothrombin mutation (P = 0.251). We identified two children born to women with HELLP syndrome (7.1 %) and one child in the control group (4.0 %) to be carriers of the G20210A prothrombin mutation (P = 0.629). In the control group, both mother and child were carriers of this mutation.
No homozygous carriers of either the FVL or the G20210A prothrombin mutation were found in any of the study subjects. None of the pre-eclamptic patients in the control group was found to be a carrier for either of the two mutations.
Overall, in 26 out of all 68 newborns (38.2 % of total; 46.2 % in the HELLP syndrome group compared with 27.6 % in the control group) growth restriction (birth weight below the tenth percentile) was found. When comparing only the fetuses investigated for both mutations (n = 53), IUGR occurred in 18 (33.96 %) of them. IUGR was significantly higher in fetuses found to be positive for a thrombophilic mutation. Seven out of the ten fetuses (70.0 %) found to be carriers of a thrombophilic mutation were growth restricted compared with 11 out of 43 without a mutation (25.6 %; P = 0.022).
Of the seven fetuses with a fetal FVL mutation, five had a birth weight below the tenth percentile. In cases in which only the fetus was identified to be heterozygous for the FVL mutation, IUGR was found in every case. Only two fetuses, who were identified as carriers of the FVL mutation with accompanying maternal mutation, had adequate growth for gestational age. Two of the three newborns positive for the G20210A prothrombin mutation, one with accompanying maternal mutation, were growth restricted.
DISCUSSION
In the present study, our results indicate a higher prevalence of FVL in women with HELLP syndrome. No difference in the prevalence of the G20210A prothrombin mutation in both groups (women and children) was observed. FVL was elevated in children of both groups compared with the published data. If the fetus was identified to be a carrier of a thrombophilic mutation, growth restriction occurred in most cases.
In the HELLP group, we found an increase in the maternal carrier rate for the FVL mutation (all heterozygous) compared with the control group [six out of 36 (16.7 %) compared with two out of 27 (7.4 %)], but the difference was not statistically significant (P = 0.282). The prevalence of FVL in our control group is double that reported for healthy pregnant women by Horstkamp et al. [9] . They found a FVL frequency of 3 % in a German population. In contrast, Gerhardt et al. [2] found a FVL frequency of 7.7 % in healthy non-pregnant women. However, in none of our FVL-positive control patients did any pregnancy complications occur. Recently, Benedetto et al. [16] reported a higher prevalence of FVL in pre-eclampsia and a slightly higher prevalence in pre-eclamptic women with HELLP syndrome. Our present findings are consistent with these results.
For the G20210A prothrombin mutation, no studies focusing exclusively on patients with HELLP syndrome are available in the literature. In pre-eclampsia, Grandone et al. [10] and Kupferminc et al. [11] reported a higher prevalence compared with uncomplicated pregnancies. Benedetto et al. [16] found a higher prevalence of the G20210A prothrombin mutation in pre-eclampsia, but did not observe any difference between the women with HELLP syndrome compared with pre-eclamptic women. In our present study, none of the women with HELLP syndrome and only one woman in the control group was found to be a heterozygous carrier of that mutation. Therefore the G20210A prothrombin mutation does not appear to be involved in the pathogenesis of HELLP syndrome.
Although the haemodynamic balance between maternal and fetal circulation is an important component of normal fetal development and pregnancy, a thrombophilic mutation of the fetus may also contribute to the pathogenesis of this disorder. Up to now, only a few conflicting studies have investigated the contribution of the fetal compartment to pregnancy complications. Wisotzkey et al. [21] investigated the prevalence of FVL and the G20210A prothrombin mutation in placentas of 35 growth-restricted fetuses. No mutation was found in their cases; however, Dizon-Townson and co-workers [22] reported conflicting results. They investigated 176 women with miscarriage and reported a 2-fold increase in the FVL carrier frequency in 12 out of 139 (8.6 %) abortuses compared with 17 out of 403 (4.2 %) unselected pregnant women. Even more remarkable, a 10-fold increase in the fetal carrier frequency in ten out of 24 (42 %) placentas with > 10 % placental infarction compared with seven out of 132 (1.9 %) placentas with < 10 % infarction was observed. In contrast with that study, Livingston et al. [14] did not find any association of maternal and/or fetal thrombophilias with severe preeclampsia, HELLP syndrome and IUGR. This finding may in part be explained by the genetic heterogeneity in the United States.
Interestingly, we found an elevated fetal carrier frequency of FVL in both groups compared with the reported prevalence in the normal population [23] [24] [25] . The prevalence of FVL in children with HELLP syndrome was 14.3 % (four out of 28) compared with 12.0 % (three out of 25) in the control group. Therefore it is not likely that a FVL or G20210A prothrombin mutation of the fetal, and indirectly the paternal, compartment contributes significantly to the specific pathophysiological mechanisms of HELLP syndrome. We observed the G20210A prothrombin mutation in two children with HELLP syndrome compared with one child in the control group [two out of 28 (7.1 %) compared with one out of 25 (4.0 %)] and an increased prevalence compared with the published data for the normal population [5, [25] [26] [27] . Due to the small number of patients, we cannot state if the fetus contributes significantly to the specific pathophysiology of HELLP syndrome.
The observation of a higher frequency of fetal mutations in our study population compared with the published data made us focus our attention on IUGR. Overall, we identified 38.2 % of all newborns as growth restricted (46.2 % in the HELLP group and 27.6 % in the control group). We found a strong association of fetal thrombophilic mutations with IUGR. In 18 (33.96 %) of the fetuses investigated for both mutations (n = 53), growth restriction occurred. Seven out of the ten fetuses (70.0 %) found to be carriers for a thrombophilic mutation were growth restricted compared with 11 out of 43 without a mutation (25.6 %; P = 0.022). Five out of the seven fetuses with a fetal FVL mutation were growth restricted. In cases in which only the fetus was identified to be heterozygous for the FVL mutation, IUGR was found in every case. Additionally, two out of the three newborns positive for the G20210A prothrombin mutation, one with accompanying maternal mutation, were growth restricted. The high prevalence of IUGR in both groups and the association of fetal thrombophilic mutations with IUGR might explain the high prevalence of FVL in the control group. These results are in accordance with the observation of DizonTownson et al. [22] . The fetal compartment seems to contribute significantly to the placental pathogenesis of IUGR.
These preliminary data highlight the necessity of more extensive studies investigating the association of maternal and/or fetal mutations with complicated pregnancies. Prospective studies should focus attention on the mother, father and the newborn.
Conclusion
The prevalence of the FVL mutation, but not of the G20210A prothrombin mutation, was higher in women suffering from HELLP syndrome, but the difference was not statistically significant. It is unlikely that a fetal FVL or a G20210A prothrombin mutation of the fetus contribute significantly to the clinical features of HELLP syndrome. Our results demonstrate a fetal contribution to IUGR. We speculate that a fetal thrombophilic mutation may lead to placental microthrombosis, which consecutively could lead to a disturbed fetoplacental blood flow and thus cause growth restriction.
